Magnefar B6

General characteristics. Structure:

Active ingredient: magnesium of hydroasparaginate of tetrahydrate of 500 mg that corresponds to 34 mg of magnesium and a pyridoxine of a hydrochloride of 5 mg;

 Excipients: cellulose microcrystallic, magnesium stearate, gipromeloz.

Pharmacological properties:

Magnesium is the cation necessary for the correct course of processes of metabolism in an organism. Takes part in the fermental reactions dependent on ATP-ase. Is the stabilizer of cellular membranes and intracellular organellas, and also mineral component of all body tissues.

Magnesium takes part in physiological processes nervous, musculoskeletal, respiratory, cardiovascular, hormonal (including sex hormones) and hemopoietic systems. Supports appropriate functioning of acoustical and optic nerves. Magnesium exerts protective impact on a cardiac muscle, interfering with its hypoxia and ischemia. It carries out a role of the anticoagulative factor and a factor preventing adjournment of calcium on walls of blood vessels. Has sedative effect, reduces neuromuscular excitability, causes the correct contractility of muscles. B6 vitamin is necessary for exchange of amino acids, takes part in metabolism of hydrocarbons and lipids, and also for hemoglobin synthesis. The combined use of magnesium and a pyridoxine promotes increase in resistance to a stress, and separate use of salts of magnesium of it does not guarantee.

Indications to use:

- conditions of insufficiency of magnesium (gipomagnezemiya) and B6 vitamin;
- conditions of the increased need for magnesium (physical and mental overfatigue, stressful situations, sleep disorders, hard physical and mental work, intensive sports activities, alarming states, the increased neuromuscular excitability, pregnancy and the period of feeding by a breast, advanced age);
- spasmophilia;
- before an initiation of treatment drugs of Sa ++;
- anemia.

Route of administration and doses:

With the preventive purpose drug is appointed to adults and children 6 years on 1 tablet 2 times a day are more senior.

In treatment drug bodies appoint to children from 6 to 12 years with Masa higher than 20 kg on 2-3 tablets a day, to adults and children 12 years on 3-6 tablets a day are more senior. In case of detection of insufficiency of B6 vitamin and magnesium, and also anemia and a spasmophilia the dose of drug can be increased to 2 tablets 3 times a day. Drug should be accepted inside, it is better after meal, washing down with a small amount of liquid.

Features of use:

The Wb MAGNEFAR applied in doses considerably exceeding recommended, can have laxative effect. Drug should not be accepted in doses, big, than on 1 tablet a day at simultaneous treatment by a levodopa. In case of the accompanying deficit of calcium, deficit of magnesium has to be eliminated prior to introduction of additional reception of calcium. At the frequent use of purgatives, alcohol, intense exercise and mental stresses the need for magnesium increases that can lead to development of deficit of magnesium in an organism.

Pregnancy and lactation
Due to the lack of clinical experience use of drug during pregnancy and feeding by a breast perhaps only according to indications and under careful medical control.

Influence on ability to driving of motor transport and to control of moving mechanisms.
At the recommended dosing, medicine does not influence psychomotor activity and does not limit ability to driving of motor transport and service of moving mechanisms.

Side effects:

It is not shown at the correct dosing of medicine. Sensitive persons have the drug MAGNEFAR V6 accepted before meal, can make sick, diarrhea or a dermahemia. Allergic reactions at hypersensitivity to Wb vitamin are possible Drug leads to an aggravation of a peptic ulcer of a stomach and 12 perstny guts.

Interaction with other medicines:

Simultaneous use of drug MAGNEFAR of Wb with antibiotics from group of tetracyclines, and also with peroral anticoagulants - first of all warfarin derivatives, and also the drugs containing phosphates, leads compounds of iron or calcium to mutual decrease in absorption from digestive tract, the pause between receptions has to be 3 hours. Drug weakens action of a levodopa. Use of Cycloserinum, gidralazin, isoniazid, Penicillaminum and oral contraceptives leads to increase in need for B6 vitamin.

Contraindications:

Drug MAGNEFAR V6 should not be accepted at a gipermagniyemiya, acute insufficiency of kidneys (the CL creatinine less than 30 ml/min.), an atrioventricular block, the myasthenia expressed to arterial hypotension, a fenilketonuriya, an allergy to vitamin of Wb, a peptic ulcer of a stomach and 12 perstny guts, severe damages of a liver at patients with a myocardial infarction. Children's age up to 6 years.

Overdose:

At normal function of kidneys oral administration of magnesium does not cause toxic reactions. However, poisoning with magnesium can develop at a renal failure. Toxic effects generally depend on the content of magnesium in blood serum. Overdose symptoms: lowering of arterial pressure, nausea, vomiting, depression, delay of reflexes, distortion of results of the electrocardiogram, respiratory depression, coma, cardiac standstill and cardioplegia, anuretic syndrome. Treatment: regidratation, artificial diuresis. At a renal failure the hemodialysis or peritoneal dialysis is necessary.

Storage conditions:

Medicine should be stored in the dry place protected from light and moisture, at a temperature not above 15-25 °C. To store in the place, unavailable to children.

Issue conditions:

Without recipe

Packaging:

On 10 tablets in blisters. 6 blisters place in packs cardboard.